AKAN
Price
$0.94
Change
-$0.23 (-19.66%)
Updated
Feb 5, 02:16 PM (EDT)
Capitalization
2.46M
Intraday BUY SELL Signals
INCR
Price
$0.87
Change
-$0.02 (-2.25%)
Updated
Feb 5, 11:06 AM (EDT)
Capitalization
48.9M
84 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AKAN vs INCR

Header iconAKAN vs INCR Comparison
Open Charts AKAN vs INCRBanner chart's image
Akanda
Price$0.94
Change-$0.23 (-19.66%)
Volume$410
Capitalization2.46M
Intercure
Price$0.87
Change-$0.02 (-2.25%)
Volume$1K
Capitalization48.9M
AKAN vs INCR Comparison Chart in %
AKAN
Daily Signal:
Gain/Loss:
INCR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AKAN vs. INCR commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKAN is a Hold and INCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (AKAN: $1.17 vs. INCR: $0.89)
Brand notoriety: AKAN and INCR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AKAN: 11% vs. INCR: 151%
Market capitalization -- AKAN: $2.46M vs. INCR: $48.9M
AKAN [@Pharmaceuticals: Generic] is valued at $2.46M. INCR’s [@Pharmaceuticals: Generic] market capitalization is $48.9M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKAN’s FA Score shows that 0 FA rating(s) are green whileINCR’s FA Score has 1 green FA rating(s).

  • AKAN’s FA Score: 0 green, 5 red.
  • INCR’s FA Score: 1 green, 4 red.
According to our system of comparison, INCR is a better buy in the long-term than AKAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKAN’s TA Score shows that 4 TA indicator(s) are bullish while INCR’s TA Score has 5 bullish TA indicator(s).

  • AKAN’s TA Score: 4 bullish, 3 bearish.
  • INCR’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, INCR is a better buy in the short-term than AKAN.

Price Growth

AKAN (@Pharmaceuticals: Generic) experienced а -23.53% price change this week, while INCR (@Pharmaceuticals: Generic) price change was -3.85% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.57%. For the same industry, the average monthly price growth was -1.57%, and the average quarterly price growth was +13.49%.

Reported Earning Dates

INCR is expected to report earnings on Apr 30, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.57% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCR($48.9M) has a higher market cap than AKAN($2.46M). INCR has higher P/E ratio than AKAN: INCR (25.48) vs AKAN (0.01). INCR YTD gains are higher at: -1.736 vs. AKAN (-48.830). AKAN has higher annual earnings (EBITDA): -2.22M vs. INCR (-39.54M). INCR has more cash in the bank: 20.3M vs. AKAN (2.52M). AKAN has less debt than INCR: AKAN (391K) vs INCR (151M). INCR has higher revenues than AKAN: INCR (273M) vs AKAN (837K).
AKANINCRAKAN / INCR
Capitalization2.46M48.9M5%
EBITDA-2.22M-39.54M6%
Gain YTD-48.830-1.7362,812%
P/E Ratio0.0125.480%
Revenue837K273M0%
Total Cash2.52M20.3M12%
Total Debt391K151M0%
FUNDAMENTALS RATINGS
INCR: Fundamental Ratings
INCR
OUTLOOK RATING
1..100
4
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
86
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
29

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKANINCR
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AKAN
Daily Signal:
Gain/Loss:
INCR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GLPI45.451.18
+2.67%
Gaming and Leisure Properties
MESO16.99-0.35
-2.02%
Mesoblast Limited
YORW32.49-0.71
-2.14%
York Water Company
ZTEK0.65-0.02
-2.28%
Zentek Ltd
ENSC0.57-0.04
-6.66%
Ensysce Biosciences

AKAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKAN has been loosely correlated with INCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if AKAN jumps, then INCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKAN
1D Price
Change %
AKAN100%
+0.86%
INCR - AKAN
54%
Loosely correlated
-4.77%
SXTC - AKAN
53%
Loosely correlated
-13.02%
PRGO - AKAN
51%
Loosely correlated
+4.03%
ALVO - AKAN
49%
Loosely correlated
-2.30%
ACB - AKAN
48%
Loosely correlated
-7.64%
More

INCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCR has been closely correlated with SXTC. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if INCR jumps, then SXTC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
-4.77%
SXTC - INCR
66%
Closely correlated
-13.02%
PRGO - INCR
56%
Loosely correlated
+4.03%
AKBA - INCR
56%
Loosely correlated
-2.84%
ALVO - INCR
54%
Loosely correlated
-2.30%
SHPH - INCR
48%
Loosely correlated
-12.50%
More